Featured Research

from universities, journals, and other organizations

Self-administered vaccine patch may protect against potentially pandemic flu viruses

Date:
September 9, 2010
Source:
American Society for Microbiology
Summary:
A self-administered patch containing tiny microneedles may effectively deliver influenza virus-like particles through the skin and protect against potentially pandemic flu viruses such as H5N1.

A self-administered patch containing tiny microneedles may effectively deliver influenza virus-like particles through the skin and protect against potentially pandemic flu viruses such as H5N1.

Researchers from the U.S. and abroad report their findings in the September 2010 issue of the journal Clinical Vaccine and Immunology.

In the United States, seasonal flu epidemics often result in over 200,000 hospitalizations and 36,000 deaths each year. New pandemic flu strains continue to emerge, such as the 2009 H1N1 virus that resulted in the first pandemic influenza outbreak in the 21st century. Conventional vaccination programs require a painful injection administered by medical personnel and can take months to develop, emphasizing the need for vaccines that can be rapidly produced at low cost and distributed within weeks.

Influenza virus-like particles (VLPs) are potentially promising vaccine candidates as they are non-infectious and have been shown to induce long-lasting immunity against pandemic influenza viruses. An abundance of dermal dendritic cells, important members of the skins' immune system, make the skin an appealing route for vaccine delivery.

In the study researchers vaccinated mice with microneedle patches containing influenza H5 VLPs derived from the H5N1 virus and found the resulting protective immunity to be equal to or higher than that induced from intramuscular inoculation. Significantly, human skin cells also responded to the influenza VLP vaccine delivered by the microneedle patch.

"Microneedle vaccination in the skin with H5 VLPs represents a promising approach for a self-administered vaccine against viruses with pandemic potential," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. J.-M. Song, Y.-C. Kim, A. S. Lipatov, M. Pearton, C. T. Davis, D.-G. Yoo, K.-M. Park, L.-M. Chen, F.-S. Quan, J. C. Birchall, R. O. Donis, M. R. Prausnitz, R. W. Compans, S.-M. Kang. Microneedle Delivery of H5N1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice. Clinical and Vaccine Immunology, 2010; 17 (9): 1381 DOI: 10.1128/CVI.00100-10

Cite This Page:

American Society for Microbiology. "Self-administered vaccine patch may protect against potentially pandemic flu viruses." ScienceDaily. ScienceDaily, 9 September 2010. <www.sciencedaily.com/releases/2010/09/100908104340.htm>.
American Society for Microbiology. (2010, September 9). Self-administered vaccine patch may protect against potentially pandemic flu viruses. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/09/100908104340.htm
American Society for Microbiology. "Self-administered vaccine patch may protect against potentially pandemic flu viruses." ScienceDaily. www.sciencedaily.com/releases/2010/09/100908104340.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins